Comparison · NCT04145349-sae
Ramucirumab + Cyclophosphamide + Vinorelbine vs Cyclophosphamide + Vinorelbine: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Ramucirumab + Cyclophosphamide + Vinorelbine vs Cyclophosphamide + Vinorelbine: serious adverse events. Trial comparisons, record NCT04145349-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04145349-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.3 | 0.145 | 0.519 | wilson | |
| Risk in group 2 | 0.3 | 0.108 | 0.603 | wilson | |
| Risk difference, group 1 minus group 2 | 0 | -0.34 | 0.291 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1 | 0.314 | 3.19 | log | |
| Odds ratio, group 1 over group 2 | 1 | 0.191 | 5.24 | log | |
| Number needed to harm | from the risk difference interval | the two groups' risks are equal |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Ramucirumab + Cyclophosphamide + Vinorelbine | Participants received the following treatments in a 28-day cycle, continuing until disease progression or a criterion for discontinuation was met.~* Ramucirumab administered intravenously at a dose of 12 mg/kg as a one-hour infusion on days 1 and 15.~* Cyclophosphamide administered orally at 25 mg/m² daily from days 1 to 28.~* Vinorelbine administered intravenously at 25 mg/m² on days 1, 8, and 15. | 6 | 20 | EG000 |
| Group 2 | Cyclophosphamide + Vinorelbine | Participants received the following treatments in a 28-day cycle, continuing until disease progression or a criterion for discontinuation was met.~* Cyclophosphamide administered orally at 25 mg/m² daily from days 1 to 28.~* Vinorelbine administered intravenously at 25 mg/m² on days 1, 8, and 15. | 3 | 10 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Baseline Up to 23 months
Source ClinicalTrials.gov
Trial
- Title
- CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor
- NCT number
- NCT04145349
- Phases
- PHASE1, PHASE2
- Conditions
- Desmoplastic Small Round Cell Tumor
- Interventions
- Ramucirumab, Cyclophosphamide, Vinorelbine
- Lead sponsor
- Eli Lilly and Company
- Results first posted
- 2025-07-20
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04145349?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04145349-sae